{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:57:28Z","timestamp":1792785448931,"version":"4.5.0"},"reference-count":45,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"Biohaven Pharmaceuticals","id":[{"id":"https:\/\/ror.org\/00m2ky193","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"published-print":{"date-parts":[[2022,1,2]]},"DOI":"10.1080\/14737167.2021.1945444","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T03:12:47Z","timestamp":1624245167000},"page":"155-166","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":22,"title":["Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis"],"prefix":"10.1080","volume":"22","author":[{"given":"Karissa","family":"Johnston","sequence":"first","affiliation":[{"name":"Broadstreet Health Economics & Outcomes Research","place":["Vancouver, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Popoff","sequence":"additional","affiliation":[{"name":"Broadstreet Health Economics & Outcomes Research","place":["Vancouver, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Deighton","sequence":"additional","affiliation":[{"name":"Broadstreet Health Economics & Outcomes Research","place":["Vancouver, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parisa","family":"Dabirvaziri","sequence":"additional","affiliation":[{"name":"Broadstreet Health Economics & Outcomes Research","place":["Vancouver, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Harris","sequence":"additional","affiliation":[{"name":"Biohaven Pharmaceuticals","place":["New Haven, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Thiry","sequence":"additional","affiliation":[{"name":"Biohaven Pharmaceuticals","place":["New Haven, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Croop","sequence":"additional","affiliation":[{"name":"Biohaven Pharmaceuticals","place":["New Haven, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Coric","sequence":"additional","affiliation":[{"name":"Biohaven Pharmaceuticals","place":["New Haven, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"L\u2019Italien","sequence":"additional","affiliation":[{"name":"Biohaven Pharmaceuticals","place":["New Haven, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Moren","sequence":"additional","affiliation":[{"name":"Island Hospital","place":["Anacortes, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,7,2]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13456"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13613"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12755"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2016.10.005"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1607358"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410381145"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13275"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)60561-2"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01110-9"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12499"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182535d20"},{"issue":"4","key":"e_1_3_6_14_1","first-page":"243","article-title":"Acute migraine headache: treatment strategies","volume":"97","author":"Mayans L","year":"2018","unstructured":"Mayans L, Walling A. Acute migraine headache: treatment strategies. Am Fam Physician. 2018;97(4):243\u2013251.","journal-title":"Am Fam Physician"},{"issue":"2","key":"e_1_3_6_15_1","first-page":"S23","article-title":"Migraine overview and summary of current and merging treatment options","volume":"25","author":"Peters G","year":"2019","unstructured":"Peters G. Migraine overview and summary of current and merging treatment options. Am J Manag Care. 2019;25(2 Suppl):S23\u2013S34.","journal-title":"Am J Manag Care"},{"key":"e_1_3_6_16_1","volume-title":"REYVOW (lasmiditan) tablets Prescribing Information","author":"Eli Lilly and Company","year":"2019","unstructured":"Eli Lilly and Company. REYVOW (lasmiditan) tablets Prescribing Information. Indianapolis, IN.: U.S. Food and Drug Administration; 2019. (Ed.^(Eds)."},{"key":"e_1_3_6_17_1","volume-title":"UBRELVY (ubrogepant) tablets Prescribing Information","author":"Allergan USA","year":"2019","unstructured":"Allergan USA. UBRELVY (ubrogepant) tablets Prescribing Information. Madison, NJ.: U.S. Food and Drug Administration; 2019. (Ed.^(Eds)."},{"key":"e_1_3_6_18_1","volume-title":"NURTEC ODT (rimegepant) orally disintegrating tablets Prescribing Information","author":"Biohaven Pharmaceuticals","year":"2020","unstructured":"Biohaven Pharmaceuticals. NURTEC ODT (rimegepant) orally disintegrating tablets Prescribing Information. New Haven, CT: U.S. Food and Drug Administration; (Ed.^(Eds), 2020."},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01132-3"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2020.1721462"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1694004"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2020.1772758"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-0974-3"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0003-1"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13791"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01138-x"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01088-4"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756285614562419"},{"key":"e_1_3_6_29_1","unstructured":"ClinicalTrials.gov. BHV3000-303: phase 3 Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine. NCT03461757. (Ed.^(Eds) (2020)"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31606-X"},{"key":"e_1_3_6_31_1","unstructured":"ClinicalTrials.gov. Efficacy Safety and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine (ACHIEVE I). NCT02828020. (Ed.^(Eds) (2019)"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813049"},{"key":"e_1_3_6_33_1","unstructured":"ClinicalTrials.gov. Efficacy Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine (ACHIEVE II). NCT02867709. (Ed.^(Eds) (2019)"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.16711"},{"key":"e_1_3_6_35_1","unstructured":"ClinicalTrials.gov. Lasmiditan compared to placebo in the acute treatment of migraine: (SAMURAI). NCT02439320. (Ed.^(Eds) (2019)"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006641"},{"key":"e_1_3_6_37_1","unstructured":"ClinicalTrials.gov. Three doses of Lasmiditan (50 mg 100 mg and 200 mg) compared to placebo in the acute treatment of migraine (SPARTAN). NCT02605174. (Ed.^(Eds) (2019)"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz134"},{"key":"e_1_3_6_39_1","unstructured":"Atlas S Touchette D Agboola F et al. Acute Treatments for Migraine: effectiveness and Value. Institute for Clinical and Economic Review February. (Ed.^(Eds) (2020)"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.01.011"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_3_6_43_1","unstructured":"Dias S Welton N Sutton A et al. NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. Unit DS (Ed.^(Eds) (2011)"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-017-0473-z"},{"key":"e_1_3_6_45_1","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.94.15_supplement.4829","article-title":"Long-Term safety of rimegepant 75 mg for the acute treatment of migraine (Study 201) (4829)","volume":"94","author":"Croop R","year":"2020","unstructured":"Croop R, Berman G, Kudrow D, et al. Long-Term safety of rimegepant 75 mg for the acute treatment of migraine (Study 201) (4829). Neurology. 2020;94 (15 Supplement).","journal-title":"Neurology"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13682"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.04.002"}],"container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737167.2021.1945444","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14737167.2021.1945444","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737167.2021.1945444","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:53:10Z","timestamp":1791287590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737167.2021.1945444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,2]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,2]]}},"alternative-id":["10.1080\/14737167.2021.1945444"],"URL":"https:\/\/doi.org\/10.1080\/14737167.2021.1945444","relation":{},"ISSN":["1473-7167","1744-8379"],"issn-type":[{"value":"1473-7167","type":"print"},{"value":"1744-8379","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-04-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}